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Abstract. Background: No clinical test is currently available and validated to measure the maximum walking speed (WS) of
multiple sclerosis (MS) patients. Since the Timed 25-Foot Walk Test (T25FW) is performed with a static start, it takes a significant
proportion of the distance for MS patients to reach their maximum pace.
Objectives: In order to capture the maximum WS and to quantify the relative impact of the accelerating phase during the first
meters, we compared the classical T25FW with a modified version (T25FW+) allowing a dynamic start after a 3 meters run-up.
Methods: Sixty-four MS patients and 30 healthy subjects performed successively the T25FW and the T25FW+.
Results: The T25FW+ was performed faster than the T25FW for the vast majority of MS and healthy subjects. In the MS
population, the mean relative gain of speed due to the dynamic start on T25FW+ was independent from the EDSS and from the
level of ambulation impairment. Compared to healthy subjects, the relative difference between dynamic versus static start was
more important in the MS population even in patients devoid of apparent gait impairment according to the T25FW.
Conclusion: The T25FW+ allows a more accurate measurement of the maximum WS of MS patients, which is a prerequisite to
reliably evaluate deceleration over longer distance tests. Indirect arguments suggest that the time to reach the maximum WS may
be partially influenced by the cognitive impairment status. The maximum WS and the capacity of MS patients to accelerate on a
specific distance may be independently regulated and assessed separately in clinical trials and rehabilitation programs.
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1. Introduction
Ambulation impairment is one of the most promi-
nent and frequent clinical feature of multiple sclerosis
(MS) [1] with major consequences on patient’s auton-
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omy. Gait disturbances have a high impact on the per-
sonal, professional and social burden of this disease [2,
3]. The onset of permanent gait limitations is often
conceived as a late process in the course of the disease,
and ambulation is only taken into account beyond the
score of 4.0 on the Expanded Disability Status Scale
(EDSS) [4]. However, several studies have suggested
that the restriction of ambulation performances might
occur much earlier than previously considered [5–7].
Furthermore, the precise monitoring of walking capac-
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ities in MS patients is gaining more and more attention,
since emerging rehabilitation techniques [8], symp-
tomatic [9] and disease modifying [10] therapies are
becoming increasingly effective with a substantial pro-
portion of patients experiencing some degree of clinical
improvement in specific conditions.
Although several alternative approaches have been
developped [11–14], the Timed 25-Foot Walk Test [15,
16] (T25FW) is currently the most widely used test to
evaluate locomotion in clinical trials. Although highly
relevant to the characterization of patients’ daily func-
tional impairment, scarce data are available in regard
of the precise gait-related physiological correlates of
the T25FW. In fact, we recently demonstrated that the
T25FW does not effectivelymeasure the real maximum
walking speed, since the mean walking speed (WS) is
paradoxically higher on a longer distance (i.e. 100 me-
ters) test [14].
Several hypotheses were proposed to explain this ap-
parent discrepancy, such as a more important influence
of the precision of the examining technician and of mo-
tivational issues in a short distance walk test. We also
speculated that the relative duration and length of the
accelerating phase during the very first meters of the
test could contribute to the slower WS observed on a
short distance walking test.
In order to investigate the potential weight of these
firstmeters of acceleration in the T25FWperformances,
we proposed a corrected version of the test where a dy-
namic start is allowed 3 meters before the starting line
(i.e. T25FW+). We assumed that 3 meters, which rep-
resent nearly 40% of the full 25-foot distance was like-
ly enough to reach a maximum walking pace for most
MS patients. Hence, this paradigm allows to exclude or
severely reduce the relative impact of the “acceleration
phase” in the test and to compare the observed mean
walking speed on the same distance with that of the
conventional T25FW (i.e. with a static start right behind
the line). To our knowledge no head-to-head compari-
son between static and dynamic starting protocols has
ever been performed among the various methodologies
previously used to assess the WS in MS [18,19].
2. Methods
Sixty-four patients with a diagnosis of relapsing-
remitting or progressive MS according to the McDon-
ald [20] criteria and 30 age and sex matched healthy
controls used as a control group were enrolled in the
study. We selected MS patients with a broad range of
walking performances with an EDSS 6.5.
The study protocol was approved by the local ethics
committee from the medical faculty of Lie`ge.
The T25FW was performed according to the pub-
lished standardized instructions [15,16].
The T25FW+ was also strictly following the guide-
lines of the T25FW [15,16], except that the subjects
were allowed to take a 3 meters run-up before the start-
ing line. This run-up was clearly demarcated on the
ground. The raters were instructed for both tests to
start the stopwatch as soon as the lead foot crossed the
starting line of the 25-foot distance, and to stop it when
the lead foot crossed the finish line.
The raters had been trained and certified for the ad-
ministration of all the tests from the Multiple Sclerosis
Functionnal Composite score (RP, PC or SB). EDSS
scores were collected by certified EDSS-raters (RP or
SB).
The T25FW and the T25FW+ were performed as the
first part of a multi-test evaluation during routine clin-
ical evaluations, in an outpatient neurological MS de-
partment, between November 2009 and October 2010.
The T25FW was first performed twice as well as the
T25FW+ after 5 minutes of break in between. For both
tests, the results were expressed as the mean time of
the 2 trials.
The Mean WS expressed in meters per second for
both tests were obviously calculated by dividing 7.62m
(i.e. 25 feet) by the time to perform the T25FW or the
T25FW+.
Non parametric unpaired t-test was used for between
group comparisons, while non parametric paired t-test
was used for within group comparisons. Pearson’s cor-
relation coefficient was used to assess the relationship
between the two tests. All statistical tests were applied
with a two-tailed analysis and 0.05 as a level of sig-
nificance, and were performed using GraphPad Prism,
version 4.0b for Macintosh, GraphPad Software, San
Diego California USA (www.graphpad.com).
3. Results
The baseline characteristics of MS patients (n = 64)
and healthy control volunteers (n = 30) are summa-
rized in Table 1. No major differences were observed
between the two populations. In the MS population,
the median EDSS was 3.0 (ranging from 0 to 6.5). The
distribution of the population throughout the different
EDSS subgroups was harmonious.
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Table 1
Characteristics of MS patients and control subjects
MS patients Healthy controls
Number of patients/controls 64 30
Gender (% female) 59 71
Age (median, range, years) 39,15–64 25,18–60
Body Mass Index (mean ± SD, kg/m2) 23,55 ± 4,2 25,18 ± 9,6
EDSS (median, range) 3.0, 0–6.5 n.a.
EDSS 0–2.0 (number of patients, %) 25 (39) n.a.
EDSS 2.5–4.0 (number of patients, %) 24 (37,5) n.a.
EDSS 4.5–6.5 (number of patients, %) 15 (23,4) n.a.
MS type (CIS/RR/SP/PP, %)1 9,4/65,6/12,5/12,5 n.a.
Disease duration (mean ± SD, range, years) 10,4 ± 9,3, 0–35 n.a.
1: CIS, Clinically Isolated Syndrome; RR, Relapsing-Remitting; SP, Secondary Progres-
sive; PP, Primary Progressive.
Fig. 1. Absolute difference between the T25FW+ and the T25FW (ΔT25FW+-T25FW) in individual MS patients (A) and healthy controls (B).
Absolute difference between the mean calculated walking speed (WS) in both tests (ΔWS (T25FW+-T25FW)) in MS patients (C) and healthy
controls (D). All results were classified by increasing T25FW.
In both healthy control volunteers and MS patients,
the two tests displayed a good correlation (Pearson’s
correlation coefficient = 0.8554 and 0.9791, both p <
0.0001, respectively).
As highlighted by individual absolute differences in
time (Figs 1A and 1B) and in mean WS (Figs 1C and
1D), the vast majority of MS patients (92%, 59/64,
Figs 1A and 1C) and healthy control volunteers (80%,
24/30, Figs 1B and 1D) performed consistently faster
on the T25FW+ than on the T25FW with varying levels
of differences between the two tests (Fig. 1).
The difference between the two tests was further con-
firmed by a mean WS that was significantly higher for
the T25FW+ compared to the T25FW in MS patients
(1.80± 0.65 vs 1.62± 0.57, respectively, mean± SD,
m/s, p < 0.0001) and healthy controls (2.46± 0.43 vs
2.31± 0.37, respectively,mean±SD,m/s,p < 0.0001)
(Fig. 2A). Ambulation speed performances were also
significantly slower forMS patients compared to that of
healthy control volunteers in both tests (p < 0.0001 for
both tests). The T25FW+ was performed consistently
faster than the T25FW in all subgroups of MS patients
stratified according to their EDSS status (0 to 2.0, 2.5 to
4.0, and 4.5 to 6.5; all p < 0.0001, Fig. 2B). In order to
dichotomizeMS patients according to their normal ver-
sus abnormal walking performances, we fixed a thresh-
old value of 4,43 seconds, corresponding to the mean
T25FW of healthy controls plus twice the standard de-
viation. We then arbitrarily separated the MS popula-
tion between the so-called “normal walker” group with




Fig. 2. Histograms depicting the mean walking speed (WS) on
the T25FW+ and T25FW in the global MS patient population and
healthy controls (A), across different levels of disability status eval-
uated through the EDSS (B), and in “normal” versus “slow” walking
MS patients (C).
a T25FW 4.43 s (n = 31, 48% of the population) and
the “slow walker” group with a T25FW>4.43s (n =
33, 52% of the population). ThemeanWS was also sig-
nificantly faster in the T25FW+ both for the “normal”
and “slow” walker MS groups (p < 0.0001, Fig. 2C).
We calculated the individual relative differences be-
tween WS in the two tests: i.e. the difference between
WS on T25FW+ minus WS on T25FW, divided by WS
on T25FW+. The mean relative difference between
WS in the two tests (Δ WS (T25FW+-T25FW)/WS
T25FW+) was significantly higher in MS patients com-
pared to controls (10.2 ± 7.7%, versus 5.7 ± 9.1%,
mean ± SD; p = 0.0148, Fig. 3A). No significant dif-
ference was found in the mean relative difference be-
tween WS in the two tests for the subgroups of MS pa-
tients at different levels of disability assessed by their
EDSS status (Fig. 3A). Themean relative difference be-
tween WS in the two tests was also significantly higher
in “normal” (10.0 ± 7.2%, mean ± SD, p = 0.0461)
and “slow” (10.4 ± 8.2%, mean ± SD, p = 0.0363)
walker MS patients compared with that of healthy con-
trol volunteers (5.7± 9.1%, mean± SD) (Fig. 3B). No
significant difference was found in this regard between
“normal” and “slow” walker MS patients (Fig. 3B).
4. Discussion
The present study show that the time to reach the
maximum WS has a significant impact in the results
of the conventional T25FW, since a run-up of 3 meters
can lead to a significantly higher mean WS measured
on the same 25 foot distance, both in healthy control
volunteers and in all subsets of MS patients. Remov-
ing part if not all of this accelerating phase to reach
the maximum pace using a 3 meters run-up before the
T25FW induced a more important difference between
the two tests in MS patients compared to healthy vol-
unteers, regardless of their EDSS status or their ambu-
lation impairment.
The difference between the two tests was also sig-
nificantly less pronounced in healthy volunteers than in
“normalwalker”MS subjects with no apparent ambula-
tory deficit. This observation may reflect the need for a
longer distance of accelerating phase to reach the same
maximum pace in MS patients, consequently perform-
ing a shorter proportion of the classical T25FW at their
real maximum WS. This indicates that the maximum
WS per se and the capacity of patients to accelerate on
a specific distance are two distinct outcome measures,
which can be differently affected by symptoms of MS.
In comparison with the maximum WS, the acceleration
capacity is likely to depend more on the motor reaction
time to a simple command, which could be altered in
case of mild cognitive dysfunction in MS patients.
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A
B
Fig. 3. Histograms depicting the mean relative difference between WS on the T25FW+ and T25FW (ΔWS (T25FW+-T25FW)/ T25FW+)
in healthy controls, the global MS patients population (A), across different levels of disability status evaluated through the EDSS (A), and in
“normal” versus “slow” walking MS patients (B).
Several studies have demonstrated that true walking
impairment or even simple postural control abnormal-
ities can be seen in the early course of MS [5–7,21]
as well as in patients where the level of disability re-
mained low or unapparent,with no clinically detectable
signs of CNS lesions according to theKurtzke function-
al system scores. Hence, beyond the typical pyramidal,
proprioceptive, and cerebellar MS symptoms affecting
ambulation, other factors that remains to be elucidat-
ed probably contribute to walking impairment in this
disease. In this regard, the potential link between ear-
ly cognitive impairment and gait disability should be
further investigated [22]. In particular, the present da-
ta strengthen the hypothesis that the attention network
and information processing speed systems, which are
frequently altered early in MS [23,24] may contribute
to gait and postural disturbances [5,22] at any stage of
the disease course.
For clinical trials particularly when addressing pro-
gressive forms of MS, as well as for the field of neu-
rorehabilitation, these results emphasize that the classi-
cal T25FW needs to be revisited with a propelled start
(T25FW+) to better capture the real maximum WS of
MS patients on short distances. Then only, should the
T25FW+ performances be compared to WS measure-
ments performed using longer distance tests such as
the Timed 100-Meters Walk Test [14]. This will allow
the development of new insightful outcome measures
through the calculation of ratios between WS measured
on short and longer distances. We think such deceler-
ation indexes may be reliable indicators of ambulation
fatigue [25], which is present even at early stages of
disease progression [26].
This refinement and improvementof ambulation out-
come measures is a necessary step to increase their sen-
sitivity and specificity in order to disentangle the ef-
fects of rehabilitation programs, disease-modifyingand
symptomatic treatments even at low levels of ambula-
tion impairment,which is major componentof patients’
disability in multiple sclerosis.
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